جستجوی استاد راهنمای دانشگاهی

• Lymphoma
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma
• +۵ مورد دیگر

Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.

Carmen Bergomمشاهده پروفایل

دانشیار

• Radiation Oncology
• Breast Cancer
• Tumor Microenvironment
• +۵ مورد دیگر

Carmen Bergom, MD, PhD, is an Associate Professor of Radiation Oncology at Washington University School of Medicine (WashU Medicine), where she joined the faculty in 2020. She holds secondary appointments in the Division of Cancer Biology and the Siteman Cancer Center. Her research focuses on leveraging genetic models to improve radiation therapy efficacy while mitigating radiation-induced cardiotoxicity , particularly in breast cancer patients. Key areas include radiation biology , tumor microenvironment , and cardio-oncology . Recent publications highlight her work in genetic mapping of radiation sensitivity (e.g., rat chromosome 3 variants), innovative imaging techniques (e.g., integrin-targeted PET), and clinical trial design for cardiovascular risk stratification. Her laboratory has pioneered the first genetic studies of radiation-induced cardiac dysfunction. Scientific awards include the Michael Fry Research Award (2021) and recognition as a Top Doctor in America (2018, 2019). She serves as Chair of the ASTRO Science Council Scientific Review Panel and co-chair of the Clinical and Experimental Research in Radiation Oncology meeting at ESTRO. Dr. Bergom treats breast cancer patients clinically and mentors students across all levels (undergraduate to postdoctoral). Her work bridges basic research with clinical applications , aiming to develop biomarkers and therapeutic targets for radiation oncology.

• Artificial Intelligence
• Bayesian Networks
• Machine Learning
• +۶ مورد دیگر

Dr. Peter J.F. Lucas is a Full Professor specializing in Datamanagement & Biometrics with over 35 years of experience in artificial intelligence, probabilistic graphical models, and clinical decision support systems. His research spans intelligent systems, machine learning, and eHealth, with a focus on applying Bayesian networks and probabilistic logic to medical and non-medical domains.

• Quantitative PET/CT and SPECT/CT Imaging
• Deep Learning in Medical Imaging
• Motion Correction Algorithms
• +۲ مورد دیگر

Chi Liu is a Professor of Radiology & Biomedical Imaging at Yale School of Medicine . He serves as Associate Director of Biomedical Imaging Technology at the Yale Biomedical Imaging Institute and Director for Research Faculty Affairs in the Radiology & Biomedical Imaging department. Education : PhD from Johns Hopkins University (2008) Postdoctoral Training : University of Washington (2010) Certification : American Board of Science in Nuclear Medicine (Nuclear Medicine Physics and Instrumentation) His research focuses on quantitative cardiac and oncological PET/CT and SPECT/CT imaging , emphasizing deep learning algorithms , reconstruction algorithms , data correction , and dynamic imaging . Key clinical applications include early detection of chemotherapy-induced cardiotoxicity , multimodality imaging of heart failure , and motion variability elimination in therapy response assessment . The 15 most recent publications reveal a strong emphasis on deep learning techniques for low-dose imaging , motion correction , and cross-tracer generalizability in PET/SPECT systems. These works span applications in cardiac imaging , neuroscience , oncology , and theranostics . Scientific Award : Bruce Hasegawa Young Investigator Medical Imaging Science Award (2012) Contact: chi.liu@yale.edu | ORCID 0000-0002-7007-1037

• Statistical Methods in Biomedical Research
• Biomarker Analysis
• Clinical Trial Design
• +۷ مورد دیگر

Todd A. Alonzo is a Professor of Research in the Department of Preventive Medicine at the University of Southern California . As Group Statistician for the Children's Oncology Group , he focuses on statistical methods for biomarker analysis, medical diagnostic testing, and clinical trial design in pediatric acute myeloid leukemia (AML). Education: B.S. in Statistics, California State Polytechnic University (1994) MS and PhD in Biostatistics, University of Washington (1997, 2000) Research Interests include: Development of statistical frameworks for diagnostic accuracy Genomic and proteomic profiling in AML Pharmacogenomic score systems for chemotherapy response Non-inferiority trial design in low-event-rate settings Health disparities in pediatric oncology Scientific Awards : Fellow, American Statistical Association (2018) Outstanding Teacher Award, International Society for Magnetic Resonance in Medicine (2017) NIH Predoctoral Cardiovascular Biostatistics Training Grant (1995) ENAR Biometrics Society Distinguished Student Paper Award (1999) WNAR Biometrics Society Best Student Oral Presentation (1999) Leadership & Service includes editorial board memberships (Biometrics, Pediatric Blood & Cancer, Biometrical Journal), reviewer for 30+ scientific journals, and roles on multiple Data Safety and Monitoring Boards. He served as President of the International Biometric Society Western Northern America Region (WNAR) in 2009.

Juliane Nguyenمشاهده پروفایل

استاد

• Molecular Engineering
• Protein-based Therapeutics
• Live Biotherapeutics
• +۷ مورد دیگر

Juliane Nguyen, PhD, is a Professor in the Department of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. She serves as Vice Chair and Director of Graduate Admissions in her department and holds an adjunct appointment as Professor of Biomedical Engineering. Dr. Nguyen is also a member of the UNC Lineberger Comprehensive Cancer Center, where she applies molecular engineering approaches to develop innovative therapeutic solutions. Dr. Nguyen's research focuses on molecular engineering to advance protein-based therapeutics, live biotherapeutics (including engineered probiotic yeast), and extracellular vesicles. Her lab develops cutting-edge technologies to treat diverse conditions including cancer, myocardial infarction, chemotherapy-induced cardiotoxicity, and inflammatory bowel diseases. Her interdisciplinary approach integrates molecular engineering, pharmaceutical sciences, and bioinformatics to create complex biologics with exceptional safety and efficacy profiles. Key research areas include developing therapeutics for cardiac repair, genetically encoded materials targeting tumor-associated macrophages, live biotherapeutics for inflammatory bowel diseases using engineered probiotic yeast, and auxetic patches for dynamic organ repair. Analysis of Dr. Nguyen's recent publications reveals a strong focus on translational research with significant contributions to cardiac repair technologies, cancer immunotherapy, inflammatory bowel disease treatments, and advanced biomaterials. Her work consistently bridges fundamental molecular engineering with clinical applications, particularly in the areas of targeted drug delivery, extracellular vesicle therapeutics, and engineered live biotherapeutics. The research demonstrates a clear trajectory toward developing clinically viable solutions for previously challenging medical conditions. Dr. Nguyen has received numerous prestigious awards and honors including the NSF CAREER Award (2018), Eshelman Innovation Award (2020), and recognition as a Fellow of the Controlled Release Society (2023). She was appointed as a Standing Member of the NIH Drug and Biologic Therapeutic Delivery Study Section (2023-2025) and serves as Executive Editor of Advanced Drug Delivery Reviews since 2021. Her Galenus Guest Professorship at ETH Zuerich (2024) and keynotes at major conferences highlight her international recognition in the field. As Director of Graduate Admissions and an active mentor, Dr. Nguyen has advised numerous PhD and Master's students who have co-authored significant publications with her. Her research is supported by competitive grants including the NSF CAREER Award and other NIH-funded projects. The Nguyen Lab maintains strong collaborations across disciplines, particularly with cardiology, oncology, and biomedical engineering researchers. She leads an interdisciplinary team focused on translating molecular engineering breakthroughs into clinically impactful therapies. The Nguyen Lab operates as a dynamic, interdisciplinary research environment combining expertise in molecular engineering, pharmaceutical sciences, and bioinformatics. The lab's mission is to revolutionize medicine by developing next-generation therapeutics that target diseases at the molecular level. Current projects focus on translating cutting-edge research into life-changing therapies for patients suffering from cancer, myocardial infarction, colitis, and other challenging conditions. The lab's innovative approach to biomolecular engineering positions it at the forefront of developing safe, effective, and personalized therapeutic solutions.

Ying Geمشاهده پروفایل

استاد

• Biological Mass Spectrometry
• Proteomics
• Metabolomics
• +۷ مورد دیگر

Ying Ge is a Professor at the University of Wisconsin–Madison, jointly appointed in the Department of Cell and Regenerative Biology and the Department of Chemistry. Her research integrates chemistry, biology, and medicine, focusing on advanced mass spectrometry-based proteomic and metabolomic technologies to address cardiovascular diseases. Education: B.S., Peking University (1997) Ph.D., Cornell University (2002) Ying Ge's work centers on developing ultra high-resolution mass spectrometry platforms for top-down proteomics and metabolomics, applied to systems biology studies of heart failure and regenerative medicine. Key projects include myofilament protein modification mapping, stem cell therapy evaluation, and biomarker discovery for cardiac conditions. The 15 most recent articles highlight her lab's methodological innovations (e.g., photocleavable surfactants, native mass spectrometry) and biological discoveries in AMPK structural heterogeneity, RBM20-mediated cardiotoxicity, and sarcomere-metabolism cross-talk during regeneration. These publications span proteomics, metabolomics, structural biology, and clinical applications.

Xian Wuمشاهده پروفایل

استادیار

• Developmental Toxicology
• Stem Cell Models
• Neurotoxicology
• +۵ مورد دیگر

Xian Wu, Ph.D., serves as a Research Assistant Professor in the Department of Pharmacology & Toxicology at East Carolina University's Brody School of Medicine. Her research leverages human stem cell models to investigate developmental vulnerabilities to environmental contaminants in cardiovascular and neural systems, with emphasis on epigenetic mechanisms and disease modeling. Dr. Wu's academic credentials include: Ph.D. in Toxicology from the University of Georgia M.S. in Biomedicine from East China Normal University B.S. in Biotechnology from Anhui University Her postdoctoral training comprised a Fellowship at the National Institute of Environmental Health Sciences and an ORISE Fellowship at the U.S. Food and Drug Administration. Research focuses on creating human stem cell-derived organoid systems to model developmental toxicology, particularly examining cardiac and neural development under chemical exposure. The laboratory employs fluorescence reporter systems and RNA-seq to identify critical vulnerability windows during early development, with recent work targeting Parkinson's disease mechanisms through dopaminergic neuron models and cardiac fibrosis via advanced organoids. Methodological innovations include high-content imaging for neurogenesis quantification and epigenetic pathway analysis. Publication trends (2016-2025) demonstrate consistent advancement in stem cell-based toxicology testing, with increasing emphasis on micro/nanoplastics risk assessment, arsenic neurotoxicity mechanisms, and doxorubicin cardiotoxicity modeling. The work bridges environmental health, epigenetics, and regenerative medicine through interdisciplinary approaches. Scientific recognition includes: 2025 SPARC Award (ECU) 2024 Top Abstract Award (Developmental Origins of Health and Disease Society) 2024 NIEHS P30 Center Travel Award 2023 ECU Research and Creative Activity Award Dr. Wu actively mentors graduate researchers including Ph.D. candidate Cate Duncan and M.S. students Kamilah Muhammad and Bailey Skeen, alongside undergraduate Bryce Tilghman. Former trainees McKyrah Brown and Monica Cross completed honors theses in the laboratory. Current grants include ECU's SPARC Award funding stem cell model development for environmental contaminant testing. The BSOM 6S-11 laboratory maintains specialized capabilities in cardiac and cerebral organoid generation, fluorescence-based toxicity screening, and RNA-seq epigenetic analysis. Collaborative networks include the National Institute of Environmental Health Sciences and ECU's Center for Human Health and the Environment, supporting translational research on developmental vulnerability periods.

Xin Zhouمشاهده پروفایل

پژوهشگر ارشد

• Computational Biology
• Health Informatics
• Cardiovascular Disease Modeling
• +۳ مورد دیگر

Dr. Xin Zhou is an Oxford-Bristol Myers Squibb Fellow at the Department of Computer Science, University of Oxford. Her research integrates computational modeling, clinical data, and experimental findings to investigate cardiac disease mechanisms and develop human-based simulations for drug evaluation. BSc and MSc in Life Sciences, Beijing Normal University DPhil in Computational Biology, University of Oxford Her work focuses on multi-scale cardiac modeling , particularly in ischemic heart disease and heart failure, exploring ionic currents, tissue conduction, and organ-level dynamics. She develops electromechanical simulations to study cardiac alternans and arrhythmic risks, translating these into clinical applications for patient stratification and pharmaceutical testing. Recent publications emphasize in silico clinical trials , sex-specific cardiometabolic analysis, and Purkinje network modeling. Collaborative efforts with clinicians and pharmaceutical partners highlight her translational approach to regulatory science. Model of the Year 2024, BioModels EPSRC Impact Acceleration Account Microsoft Research Project Award Recognition Award, University of Oxford She supervises PhD and MSc students in computational cardiology, while serving on the editorial board of Frontiers in Physiology . Her current projects involve digital twinning and predictive cardiac safety models to reduce animal testing reliance.

Steff Lewisمشاهده پروفایل

استاد

• Medical Statistics
• Clinical Trials
• Epidemiology
• +۳ مورد دیگر

Steff Lewis is a Professor of Medical Statistics at the University of Edinburgh , affiliated with the Usher Institute within the College of Medicine and Veterinary Medicine . She leads the statistics group at the Edinburgh Clinical Trials Unit and holds roles in the Deanery of Molecular, Genetic and Population Health Sciences . Her expertise spans meta-analysis, randomized trial design, and clinical trial governance, with involvement in Cochrane Collaboration and UK Clinical Research Collaboration initiatives. Education: MSc and PhD in Medical Statistics. Research Interests: Focuses on methodological advancements in clinical trial reporting (e.g., CONSORT and SPIRIT guidelines), cardiovascular outcomes (e.g., SCOT-HEART trial), stroke prevention (ASPIRING trial), and ethical data management. She actively contributes to international standards for trial protocols, anonymization practices, and statistical validation. Recent Contributions: Over 200 peer-reviewed articles and 37 ongoing projects, including leadership in trials assessing antiplatelet therapies, Paget’s disease interventions, and pediatric asthma treatments. Collaborates globally on guidelines for randomized trials and data-sharing protocols. Grants & Teams: Principal or co-investigator on projects funded by NIHR, BHF, and ESRC, including trials on iron therapy in critical care (INTACT-2) and cannabinoid treatments for endometriosis pain (ENDO-CAN). Leads multidisciplinary teams integrating statistical rigor with clinical innovation. Labs/Teams: Embedded within the Edinburgh Clinical Trials Unit and the Centre for Population Health Sciences , fostering collaborative research across molecular, genetic, and public health domains.

Joanne Wangمشاهده پروفایل

استاد

• Blood-brain and blood-csf barriers
• Pharmacokinetics-Pharmacodynamics
• Pharmacology
• +۵ مورد دیگر

Joanne Wang is Professor of Pharmaceutics at the University of Washington School of Pharmacy and an Affiliate Investigator at the Fred Hutchinson Cancer Research Center. She holds additional appointments in multiple research centers including the Obstetric-fetal Pharmacology Research Unit (OPRU), Plein Center for Aging Faculty, and Pharmaceutics Faculty. Her educational background includes: PhD in Pharmaceutical Chemistry, University of California, San Francisco (UCSF) MS in Biochemistry, University of Illinois at Chicago BS in Biochemistry, Peking University Dr. Wang's research focuses on solute carrier (SLC) and ATP-binding cassette (ABC) transporters that shuttle drugs, nutrients, neurotransmitters, and hormones across cell membranes. Her work encompasses elucidating mechanisms and clinical impact of transporters in nutrient and drug disposition and their potential as drug targets. Ongoing projects include identification and functional characterization of transporters in human placenta, mechanisms of drug secretion into breastmilk using PBPK modeling, and investigation of transporters in the disposition of meta-iodobenzylguanidine for cancer therapy. Analysis of her recent publications reveals a strong emphasis on transporter-mediated drug disposition in special populations, particularly during pregnancy and lactation, and at the blood-brain barrier. Her work spans from basic transporter characterization to clinical applications, with increasing focus on translational aspects including PBPK modeling and clinical implications of transporter polymorphisms. Dr. Wang is actively involved in mentoring, as evidenced by her lab accepting students. Her research has been supported by significant grants including a UC2 grant from NICHD for placental transporter research. Her multidisciplinary approach integrates in vitro models, in vitro-in vivo extrapolation, and PBPK modeling to address critical questions in drug disposition. She is affiliated with several research centers including the Obstetric-fetal Pharmacology Research Unit (OPRU), Plein Center for Aging, and the Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH), reflecting the breadth and impact of her work across multiple domains of pharmacology and therapeutics.

Martin Frommمشاهده پروفایل

استاد

• Biomarkers for transporter-mediated drug-drug interactions
• Medication safety (oncology, geriatrics)
• Mass spectrometry and metabolomics
• +۲ مورد دیگر

Martin Fromm is a Professor of Clinical Pharmacology and Toxicology at Friedrich-Alexander University Erlangen-Nürnberg, where he has served as Director of the Institute of Experimental and Clinical Pharmacology and Toxicology since 2004. His career includes prior roles as Acting Professor (2002–2004), Group Leader (1999–2002), and postdoctoral fellowships at the Dr. Margarete-Fischer-Bosch Institute (1992–1996) and Vanderbilt University (1997–1999). Research Focus: Mechanisms of variable drug effects, drug transporters, medication safety, and biomarker development for transporter-mediated drug interactions. Publications: Over 170 original articles and 49 reviews with an h-index of 76 (24,000+ citations). Leadership: Chair of the University Hospital Erlangen's drug utilization committee and steering board of the Center of Clinical Studies. Scientific Awards: Top 3% Highly Cited Researcher (AD Scientific Index 2022–2024) Top 2% Highly Cited Researcher (Stanford List 2023) MSD Health Award (2021) Paul-Martini-Award (2001) Presidential Trainee Award (1998) Research Trends: His recent work integrates metabolomics, machine learning (LC-MS methods), and clinical studies to enhance medication safety in oncology and geriatrics. Earlier studies focus on transporter proteins (e.g., OCT2, MATE1, P-glycoprotein) and their role in drug absorption, metabolism, and interactions. Grants & Collaborations: Funded by DFG, BMBF, BMG, and Deutsche Krebshilfe. Active in ethics committees and clinical pharmacology societies.

• Toxicology
• Environmental Toxicology
• Nanomaterial Toxicity
• +۳ مورد دیگر

Hans Bouwmeester is a Full Professor in Toxicology at Wageningen University & Research, specializing in chemical risk assessment, nanomaterial toxicity, and in vitro modeling. His work focuses on integrating artificial intelligence and physiologically based kinetic (PBK) models to predict toxic effects of contaminants like organophosphate pesticides, microplastics, and mycotoxins. He leads projects exploring the health impacts of foodborne contaminants in inflammatory bowel disease and developing animal-free testing methods. Key collaborations include EU initiatives like the ONTOX project and the GUTTEST program, which utilize advanced in vitro models such as gut-on-a-chip systems. Research interests span toxicokinetics, nanoplastics exposure, and the application of Bayesian networks for nanomaterial hazard ranking. His team addresses translational challenges in linking in vitro data to in vivo outcomes, with a focus on bile acid metabolism and cardiotoxicity prediction. Bouwmeester has supervised over 10 PhD candidates, including studies on microplastic hazard assessment, nanomaterial gastrointestinal fate, and AI-driven data extraction for risk assessment. Notable contributions include datasets on nanoplastics' protein corona effects and transcriptomic analyses of intestinal cell responses. His work is published in journals like Ecotoxicology and Environmental Safety , Toxicology , and Environmental Science & Technology , emphasizing open-access research and interdisciplinary approaches to chemical safety.

Rada Savicمشاهده پروفایل

استاد

• Pharmacometrics
• Systems Pharmacology
• Precision Medicine
• +۸ مورد دیگر

Rada Savic is a Professor in the Department of Bioengineering and Therapeutic Sciences at the University of California San Francisco (UCSF), with a focus on computational pharmacology and precision medicine. She serves as Codirector of the Pharmaceutical Sciences and Pharmacogenomics Graduate Program (PSPG) and is affiliated with the Quantitative Biosciences Institute (QBI). PhD, Pharmacometrics, Uppsala University (2008) MS, Biomedical Sciences, Uppsala University (2004) BSc, Pharmacy, University of Belgrade (2003) Her research integrates computational methods to study drug-disease interactions across molecular to whole-body scales, particularly in tuberculosis, HIV, malaria, and pediatric pharmacology. Key areas include pharmacometrics, systems pharmacology, precision dosing, and translational modeling. Recent work examines drug penetration in tuberculosis lesions, regimen optimization for drug-resistant infections, and pregnancy-related pharmacodynamic models for malaria. She has published extensively in journals like Nature Communications , Clinical Infectious Diseases , and Antimicrobial Agents and Chemotherapy . Leon I. Goldberg Early Investigator Award (2021) UCSF KL2 Career Award (2013) PhRMA Foundation Research Grant (2013) She leads NIH-funded tuberculosis consortia and contributes to global health initiatives through malaria and HIV pharmacology studies. Her collaborations span institutions including University of Belgrade, Uppsala University, and CDC Tuberculosis Trials Consortium.

• Bioethics
• Cardiology
• Cardio-Oncology
• +۱۰ مورد دیگر

Sarah C. Hull, MD, MBE is an Associate Professor of Medicine (Cardiology) at Yale School of Medicine, where she serves as Associate Director of the Program for Biomedical Ethics and Cardiology Course Director. She is affiliated with the Department of Internal Medicine, Cardio-Oncology Program, Cardiovascular Imaging Program, and Yale Cancer Center. Education: AB, Biochemical Sciences, Harvard University (2003) MD, University of Pennsylvania School of Medicine (2008) MBE, University of Pennsylvania School of Medicine (2008) Residency, Hospital of the University of Pennsylvania (2011) Fellowship, Yale University School of Medicine (2014) Her research and scholarly work focus on bioethics in cardiology and public health, with key interests in end-of-life care, LVAD deactivation, shared decision-making in cardio-oncology, nutrition ethics, vaccine ethics, and reproductive health ethics. She advocates for integrating ethical frameworks into clinical cardiology practice and medical education. Her work often addresses moral uncertainty, physician-patient communication, and systemic inequities in healthcare access. Recent publications highlight trends in cardioethics , exploring AI's role in moral agency, ethical boundaries in medicine, and curriculum development for ethics training in cardiology. She also contributes to cardio-oncology research, particularly in predicting cardiovascular outcomes in cancer survivors using advanced imaging. Scientific Awards: Bohmfalk Prize for Teaching in Basic Sciences (2021) Sarah C. Hull is actively involved in medical education and ethics leadership. She advises on clinical ethics policy and collaborates with interdisciplinary teams across Yale. She has no listed advisees or grants in the provided text, but her role as Associate Director suggests mentorship and program leadership. She is part of research teams in cardio-oncology and ethics, contributing to collaborative publications. Labs and Teams: She collaborates with researchers in the Cardio-Oncology Program and the Program for Biomedical Ethics, and is a frequent co-author with experts in cardiology, neurology, and oncology at Yale.